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Purpose: Demonstrating efﬁcacy of potential disease-modifying OA
drugs (DMOAD) requires long treatment times and a large number of
subjects, resulting in expensive clinical trials. An important risk of such
studies is the absence of beneﬁcial effect of the drug. Accurate prediction
of the doses that would result in cartilage protection and joint preservation
would help minimize this risk. Although dose may be extrapolated from
pre-clinical studies, the lack of approved DMOADs obscures the clinical
predictive capability of the OA animal models. Here we describe a trans-
lational pharmacology strategy using TIINE (a type II collagen neoepitope
assay) to evaluate MMP-13 inhibitors for the treatment of OA
Methods: The MMP-13 inhibitors belong to the class of compounds that
bind the S′1 pocket of the enzyme providing good potency (Ki 2−6 nM)
and selectivity (>4000 fold over 15 other MMPs-, ADAMTS-4 and -5, and
TACE). TIINE was measured using a sandwich immunoassay and an LC-
MS/MS assay speciﬁc for the 45-mer peptide. Rat medial meniscal tear
(MMT) and dog partial medial meniscectomy (pMx) were performed at
Bolder BioPath as previously described. All studies were approved by
the Institutional Animal Care and Use Committees.
Results: Studies in vitro showed that TIINE was generated by addition
of active MMP-13 to de-vitalized cartilage in a time- and concentration-
dependent manner, which was inhibited by MMP-13 inhibitors. Because
TIINE was also generated by addition of other MMPs, this biomarker is
not speciﬁc for MMP-13 activity. In vivo, TIINE was upregulated about two
fold in the urine from OA patients in contrast to age-matched controls. To
understand the role of MMP-13 in the generation of such OA-associated
TIINE elevation, TIINE modulation was evaluated in animal models of OA,
and in response to MMP-13 selective inhibitors. In the rat MMT, TIINE
was elevated in the synovial ﬂuid (SF) from the operated knee, but not
the contralateral knee, and it was inhibited in a time- and dose-dependent
manner following oral administration of an MMP-13 inhibitor to a maxi-
mum of ~50%. Similar TIINE inhibition in the SF and urine was observed
at the end of a 4-wk study (BID, prophylactic), and maximal inhibition
correlated with cartilage protection as evaluated by histology. All animals
and human subjects evaluated to date excrete some amount of TIINE
in their urine (which is age-dependent). Single dose oral administration
of MMP-13 inhibitor to skeletally-mature beagle dogs (naive) inhibited
baseline urinary TIINE in a time- and dose-dependent manner up to
~50%. In the 4-wk dog pMx model, MMP-13 inhibitors (BID, prophylactic)
protected cartilage degeneration at exposures that inhibited TIINE ~45%
at 2, 3 and 4 wks. These results suggest that doses that result in ~45%
inhibition of TIINE in early clinical trials may protect cartilage degradation
and joint structure in Phase 2−3 studies. In previous clinical studies with
broader spectrum MMP inhibitors, urinary TIINE was found to be inhibited
in both human healthy volunteers and OA patients.
Conclusions: The proposed translational pharmacology strategy in-
cludes: (1) determine drug plasma and/or SF concentration required for
maximum TIINE inhibition in urine of naive and/or OA animals, (2) estab-
lish correlation between TIINE inhibition and cartilage protection in animal
models of OA, (3) evaluate TIINE inhibition in healthy volunteers and/or
OA patients in early clinical trials, and (4) in POC studies, use the doses
that resulted in sufﬁcient inhibition of TIINE from the FIH studies and that
was associated with cartilage protection in pre-clinical studies.
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Purpose: The late stage of endochondral ossiﬁcation including chondro-
cyte hypertrophy, cartilage matrix degradation, and vascular invasion are
known to be crucial not only in physiological skeletal growth, but also in
cartilage destruction and osteophyte formation during osteoarthritis pro-
gression. Since the mechanism underlying these coordinated sequential
steps remains an enigma, this study sought to identify the transcription
factor and the related signals that control the stage.
Methods: A screen of transcription factors was performed using mouse
chondrogenic ATDC5 cells and HeLa cells transfected with a luciferase-
reporter construct containing a promoter of type X collagen (COL10), the
marker for chondrocyte hypertrophy. The expression patterns were exam-
ined by immunohistochemistry of mouse growth plates and by real-time
RT-PCR during insulin-induced differentiation of ATDC5 cells. Subcellu-
lar localization was examined by ﬂuorescence microscope. Functional
studies were performed using stable lines of ATDC5 cells with retroviral
overexpression of HIF2A, and those with the dominant negative (DN)
mutant or the small interfering RNA (siRNA). Transcriptional activity was
determined by luciferase assay, and the speciﬁc binding between HIF2A
protein and the identiﬁed region was veriﬁed by electrophoretic mobility
shift assay (EMSA) and chromatin immunoprecipitation (ChIP) assay.
Physiological function of HIF2A was assessed by histological comparison
of the skeletal phenotypes of heterozygous HIF2A-deﬁcient (HIF2A+/−)
mice with those of the wild-type littemates (E16.5), since HIF2A−/− mice
died in the early embryonic stage.
Results: Among over 100 transcription factors expressed in chondro-
cytes, hypoxia-inducible factor 2a (HIF2A), an a-unit member of the HIF
family, most strongly stimulated the COL10 promoter activity. HIF2A was
localized in the pre-hypertrophic and hypertrophic zones of the growth
plate; and the expression increased during differentiation of ATDC5 cells
in association not only with COL10 expression, but also with expressions
of matrix metalloproteinase 13 (MMP13) and vascular endothelial growth
factor (VEGF), crucial factors for matrix degradation and vascular inva-
sion, respectively. Expressions of COL10, MMP13 and VEGF, as well as
ALP and Alizarin red stainings, were enhanced by the HIF2A overexpres-
sion in ATDC5 cells, but were suppressed by the DN mutant or the gene
silencing through siRNA. The promoter activities of the three genes were
enhanced by the HIF2A overexpression. Deletion and mutation analyses
identiﬁed the respective responsive elements, which were conﬁrmed to
show speciﬁc binding with HIF2A by EMSA and ChIP assay. The HIF
family is known to work as a heterodimer of a-unit and b-unit members.
Our search for the b-unit partner found that aryl hydrocarbon receptor
nuclear translocator-like (ARNTL, also known as BMAL1), which was
co-localized with HIF2A in the nucleus of differentiated chondrocytes,
most strongly enhanced the transactivation of the three promoters by
HIF2A, and was necessary for the speciﬁc bindings with the responsive
elements and HIF2A. Finally, the HIF2A+/− mice were conﬁrmed to exhibit
dwarﬁsm with impairment of the late stage of endochondral ossiﬁcation
in the growth plate cartilage.
Conclusions: HIF2A is the crucial transcription factor that controls the
late stage of endochondral ossiﬁcation through direct transactivation of
COL10, MMP13 and VEGF. Elucidation of the signals related to HIF2A
will lead to further understanding of the molecular background of os-
teoarthritis.
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Purpose: Chondrocytes in articular cartilage developing OA show deviant
behavior. They seem to display a recapitulation of chondrocyte differenti-
ation similar to chondrocyte hypertrophy in the growth plate. In the growth
plate, Indian Hedgehog (Ihh) blocks terminal differentiation by keeping the
chondrocytes in a pre-hypertrophic state. Loss of Ihh expression releases
this block and allows the chondrocytes to undergo further differentiation.
This led to the hypothesis that with age, which is the primary risk factor
for OA, the expression of Ihh might be distorted in articular cartilage.
Methods: C57Bl/6 mice were sacriﬁced at 3, 6, 8, 10, 12, 14, 18, and
20 months of age. Knee joints were isolated for histology. Immunohisto-
chemistry was performed staining the sections for Ihh. Tibial cartilage was
scored for immunopositive cells using a computerized imaging system.
We additionally studied Ihh expression by immunohistochemistry in carti-
lage during experimental OA induced in C57Bl/6 mice by either injection
of collagenase (14, 21 and 42 days) or by destabilization of the medial
meniscus (DMM model) (8 weeks). Ihh expression in spontaneous OA
was analyzed in STR/ort mice aged 8 weeks and 3, 6, 9 and 12 months.
Results: Young mice expressed abundant Ihh in chondrocytes of the
articular cartilage. With age the number of Ihh immunopositive cells
rapidly declined. The number of Ihh positive cells declined 72% by
6 months of age compared to 3-month-old mice and declined even further
after that. In lateral tibial cartilage the response was similar, but with a
